Randomized Implementation of a Primary Human Papillomavirus Testing-based Cervical Cancer Screening Protocol for Women 34 to 69 Years in Norway

被引:14
作者
Nyga, Mari [1 ,11 ]
Engesaeter, Birgit [1 ]
Castle, Philip E. [2 ,3 ]
Berland, Jannicke Mohr [4 ]
Eide, Maj Liv [5 ]
Iversen, Ole Erik [6 ,7 ]
Jonassen, Christine Monceyron [8 ]
Christiansen, Irene Kraus [9 ]
Vintermyr, Olav Karsten [7 ,10 ]
Trope, Ameli [1 ]
机构
[1] Canc Registry Norway, Oslo, Norway
[2] NCI, Div Canc Prevent, NIH, Rockville, MD USA
[3] NCI, Div Canc Epidemiol & Genet, NIH, Rockville, MD USA
[4] Stavanger Univ Hosp, Stavanger, Rogaland, Norway
[5] Trondheim Reg & Univ Hosp, Trondheim, Norway
[6] Univ Bergen, Inst Clin Sci, Bergen, Norway
[7] Haukeland Hosp, Bergen, Norway
[8] Ostfold Hosp Trust, Ctr Lab Med, Gralum, Norway
[9] Akershus Univ Hosp, Lorenskog, Norway
[10] Univ Bergen, Gades Lab Pathol, Bergen, Norway
[11] Canc Reg istry Norway, Res Dept, Postbox Majorstuen 5313, N-0304 Oslo, Norway
关键词
INTRAEPITHELIAL NEOPLASIA; FOLLOW-UP; CYTOLOGY; RISK; PREVENTION; TRIAGE;
D O I
10.1158/1055-9965.EPI-22-0340
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Cervical cancer screening programs are facing a programmatic shift where screening protocol based on human papillomavirus testing (HPV-Screening protocol) is replacing the liquid-based cytology (LBC-Screening protocol). For safe technol-ogy transfer within the nationwide screening programme in Nor-way, HPV-Screening protocol was implemented randomized to compare the real-world effectiveness of HPV-Screening protocol and LBC-Screening protocol at the first screening round. Methods: Among 302,295 women ages 34 to 69 years scheduled to attend screening from February 2015 to June 2017, 157,447 attended. A total of 77,207 were randomly allocated to the HPV-Screening protocol and 80,240 were allocated to the LBC-Screening protocol. All women were followed up for 18 months. Results: The HPV-Screening protocol resulted in a relative increase of 60% in the detection of cervical intraepithelial neoplasia (CIN) grade 2 or worse [risk ratio (RR) = 1.6, 95% confidence interval (CI) = 1.5-1.7], 40% in CIN grade 3 or worse (RR = 1.4, 95% CI = 1.3-1.6), 40% in cancer (RR = 1.4, 95% CI = 1.0-2.1), and 60% in colposcopy referrals (RR = 1.6, 95% CI = 1.5-1.6) compared with LBC-Screening. The perfor-mance of both protocols was age dependent, being more effective in women ages under 50 years. Conclusions: The HPV-Screening protocol was well accepted by women in Norway and detected more CIN2, CIN3, and cancers compared with the LBC-Screening protocol.Impact: A randomized implementation of the HPV-Screening protocol with real-world assessment enabled a gradual, quality assured, and safe technology transition. HPV-based screening protocol may further be improved by using HPV genotyping and age-specific referral algorithms.
引用
收藏
页码:1812 / 1822
页数:11
相关论文
共 40 条
  • [1] Introduction of primary screening using high-risk HPV DNA detection in the Dutch cervical cancer screening programme: a population-based cohort study
    Aitken, Clare A.
    van Agt, Heleen M. E.
    Siebers, Albert G.
    van Kemenade, Folkert J.
    Niesters, Hubert G. M.
    Melchers, Willem J. G.
    Vedder, Judith E. M.
    Schuurman, Rob
    van den Brule, Adriaan J. C.
    van der Linden, Hans C.
    Hinrichs, John W. J.
    Molijn, Anco
    Hoogduin, Klaas J.
    van Hemel, Bettien M.
    de Kok, Inge M. C. M.
    [J]. BMC MEDICINE, 2019, 17 (01)
  • [2] Attendance to cervical cancer screening among Roma and non-Roma women living in North-Western region of Romania
    Andreassen, Trude
    Melnic, Adriana
    Figueiredo, Rejane
    Moen, Kare
    Suteu, Ofelia
    Nicula, Florian
    Ursin, Giske
    Weiderpass, Elisabete
    [J]. INTERNATIONAL JOURNAL OF PUBLIC HEALTH, 2018, 63 (05) : 609 - 619
  • [3] Anttila A., 2015, EUROPEAN GUIDELINES
  • [4] 2020 list of human papillomavirus assays suitable for primary cervical cancer screening
    Arbyn, Marc
    Simon, Marie
    Peeters, Eliana
    Xu, Lan
    Meijer, Chris J. L. M.
    Berkhof, Johannes
    Cuschieri, Kate
    Bonde, Jesper
    Vanlencak, Anja Ostrbenk
    Zhao, Fang-Hui
    Rezhake, Remila
    Gultekin, Murat
    Dillner, Joakim
    de Sanjose, Silvia
    Canfell, Karen
    Hillemanns, Peter
    Almonte, Maribel
    Wentzensen, Nicolas
    Poljak, Mario
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (08) : 1083 - 1095
  • [5] Evidence Regarding Human Papillomavirus Testing in Secondary Prevention of Cervical Cancer
    Arbyn, Marc
    Ronco, Guglielmo
    Anttila, Ahti
    Meijer, Chris J. L. M.
    Poljak, Mario
    Ogilvie, Gina
    Koliopoulos, George
    Naucler, Pontus
    Sankaranarayanan, Rengaswamy
    Peto, Julian
    [J]. VACCINE, 2012, 30 : F88 - F99
  • [6] Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway
    Burger, E. A.
    Ortendahl, J. D.
    Sy, S.
    Kristiansen, I. S.
    Kim, J. J.
    [J]. BRITISH JOURNAL OF CANCER, 2012, 106 (09) : 1571 - 1578
  • [7] Darum A, 2015, VEILEDER GYNEKOLOGIS
  • [8] Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study
    Dillner, Joalim
    Rebolj, Matejka
    Birembaut, Philippe
    Petry, Karl-Ulrich
    Szarewski, Anne
    Munk, Christian
    de Sanjose, Silvia
    Naucler, Pontus
    Lloveras, Belen
    Kjaer, Susanne
    Cuzick, Jack
    van Ballegooijen, Marjolein
    Clavel, Christine
    Iftner, Thomas
    [J]. BRITISH MEDICAL JOURNAL, 2008, 337 (7676): : a1754
  • [9] Quality assurance of human papillomavirus (HPV) testing in the implementation of HPV primary screening in Norway: an inter-laboratory reproducibility study
    Engesaeter, Birgit
    Hidle, Bianca van Diermen
    Hansen, Mona
    Moltu, Pia
    Staby, Kjersti Mangseth
    Borchgrevink-Persen, Siri
    Vintermyr, Olav K.
    Lonnberg, Stefan
    Nygard, Mari
    Janssen, Emiel A. M.
    Castle, Philip E.
    Christiansen, Irene Kraus
    [J]. BMC INFECTIOUS DISEASES, 2016, 16
  • [10] Finnish Cancer Registry, RAND HLTH SERV STUD